[HTML][HTML] Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response
F Filippini, M Giacomelli, C Bazzani, M Fredi… - BMC medicine, 2023 - Springer
Background The impact of immunosuppressive therapies on the efficacy of vaccines to
SARS-CoV-2 is not completely clarified. We analyzed humoral and T cell-mediated …
SARS-CoV-2 is not completely clarified. We analyzed humoral and T cell-mediated …
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls
F Kartnig, D Mrak, E Simader, S Tobudic… - Annals of the …, 2023 - ard.bmj.com
Objectives A third COVID-19 vaccination is recommended for immunosuppressed patients.
However, data on immunogenicity and safety of a third COVID-19 vaccination in patients …
However, data on immunogenicity and safety of a third COVID-19 vaccination in patients …
Differential cellular and humoral immune responses in immunocompromised individuals following multiple SARS-CoV-2 vaccinations
RT Meredith, MD Bermingham, K Bentley… - Frontiers in Cellular …, 2023 - frontiersin.org
Introduction The heterogeneity of the immunocompromised population means some
individuals may exhibit variable, weak or reduced vaccine-induced immune responses …
individuals may exhibit variable, weak or reduced vaccine-induced immune responses …
[HTML][HTML] B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV
J Polvere, M Fabbiani, G Pastore, I Rancan… - Communications …, 2023 - nature.com
Background Limited longitudinal data are available on immune response to mRNA SARS-
CoV-2 vaccination in people living with HIV (PLWHIV); therefore, new evidence on induction …
CoV-2 vaccination in people living with HIV (PLWHIV); therefore, new evidence on induction …
[HTML][HTML] Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional …
Introduction Immunocompromised patients have been shown to have an impaired immune
response to COVID-19 vaccines. Methods Here we compared the B-cell, T-cell and …
response to COVID-19 vaccines. Methods Here we compared the B-cell, T-cell and …
Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy
D Firinu, G Fenu, G Sanna, GA Costanzo, A Perra… - Journal of …, 2022 - Elsevier
Objective to investigate the responses to mRNA COVID-19 vaccines in a cohort of
immunosuppressed patients affected by immune-mediated inflammatory diseases (IMID) …
immunosuppressed patients affected by immune-mediated inflammatory diseases (IMID) …
Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination
HK Lee, MA Hoechstetter, M Buchner… - Blood …, 2023 - ashpublications.org
Patients with chronic lymphocytic leukemia (CLL) treated with B-cell pathway inhibitors and
anti-CD20 antibodies exhibit low humoral response rates following SARS-CoV-2 …
anti-CD20 antibodies exhibit low humoral response rates following SARS-CoV-2 …
Susceptibility to COVID-19 and immunologic response to vaccination in patients with immune-mediated inflammatory diseases
Immune-mediated inflammatory diseases (IMIDs) are a highly heterogeneous group of
diseases that share a common etiology of immune dysregulation, such as rheumatoid …
diseases that share a common etiology of immune dysregulation, such as rheumatoid …
B cell reconstitution is associated with COVID-19 booster vaccine responsiveness in patients previously seronegative treated with rituximab
K Schultz, D Jannat-Khah, R Spiera - The Journal of Rheumatology, 2023 - jrheum.org
Objective To assess factors associated with serologic response to the coronavirus 2019
(COVID-19) booster vaccine in patients with autoimmune rheumatic diseases treated with …
(COVID-19) booster vaccine in patients with autoimmune rheumatic diseases treated with …
[HTML][HTML] AT cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection
S Boulton, J Poutou, R Gill, N Alluqmani, X He… - … Therapy-Methods & …, 2023 - cell.com
SARS-CoV-2, the etiological agent behind the coronavirus disease 2019 (COVID-19)
pandemic, has continued to mutate and create new variants with increased resistance …
pandemic, has continued to mutate and create new variants with increased resistance …